PLOD3 and colorectal carcinoma: CRCs with higher PLOD3 showed a lower ImmuneScore, TMB, a higher TIDE score, and patients with MSS tended to have higher PLOD3 expression, suggesting the potential for immunotherapy resistance in CRC patients, which was validated in an immunotherapy treated cohort.